Liver Cirrhosis - Pipeline Review, H2 2017

Date: August 16, 2017
Pages: 90
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L32A25C0F0BEN
Leaflet:

Download PDF Leaflet

Liver Cirrhosis - Pipeline Review, H2 2017
Liver Cirrhosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis - Overview
Liver Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis - Companies Involved in Therapeutics Development
Conatus Pharmaceuticals Inc
Galectin Therapeutics Inc
Gilead Sciences Inc
Human Stem Cells Institute
Immunitor Inc
International Stem Cell Corp
Ocera Therapeutics Inc
Pharmicell Co Ltd
VESSL Therapeutics Ltd
Liver Cirrhosis - Drug Profiles
BCD-800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-LC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gemacell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis - Dormant Projects
Liver Cirrhosis - Discontinued Products
Liver Cirrhosis - Product Development Milestones
Featured News & Press Releases
Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Liver Cirrhosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H2 2017
Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2017
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2017
Liver Cirrhosis - Pipeline by Immunitor Inc, H2 2017
Liver Cirrhosis - Pipeline by International Stem Cell Corp, H2 2017
Liver Cirrhosis - Pipeline by Ocera Therapeutics Inc, H2 2017
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H2 2017
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H2 2017
Liver Cirrhosis - Dormant Projects, H2 2017
Liver Cirrhosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Liver Cirrhosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Top 10 Stage and Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Conatus Pharmaceuticals Inc
Galectin Therapeutics Inc
Gilead Sciences Inc
Human Stem Cells Institute
Immunitor Inc
International Stem Cell Corp
Ocera Therapeutics Inc
Pharmicell Co Ltd
VESSL Therapeutics Ltd
Skip to top


Cirrhosis - Pipeline Review, H2 2014 US$ 1,700.00 Jul, 2014 · 67 pages

Ask Your Question

Liver Cirrhosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: